Drs. Paul Paik, Keith Kerr, and Ross Camidge take us through testing considerations for MET exon 14 skipping mutations and optimal treatment approaches once a mutation is detected. They also discuss the emerging data and how to apply what we’re learning to everyday clinical practice.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Paul K. Paik, MD
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Contracted Research: Bicara, EMD Serono
Consulting Fees: Bicara, EMD Serono, Janssen, Mirati, Takeda
Honoraria: Bicara, EMD Serono, Janssen, Mirati, Novartis, Takeda
D. Ross Camidge, MD, PhD
Director, Thoracic Oncology
University of Colorado Cancer Center
Consulting Fees: AbbVie, Anheart, Beigene, Eli Lilly, Imagene, Immunocore, Janssen, Mirati, Prelude, Seattle Genetics, Valence
Company-sponsored trials at institution: AbbVie, AstraZeneca, Blueprint, Dizal, Inhibrx, Karyopharm, Nuvalent, Pfizer, Phosplatin, Psioxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point, Verastem
Prof. Keith M. Kerr
Department of Pathology
Aberdeen University School of Medicine &
Aberdeen Royal Infirmary
Consulting Fees: AbbVie, Amgen, AstraZeneca, Archer Diagnostics, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Debiopharm, Diaceutics, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Roche Diagnostics/Ventana, Sanofi
Honoraria: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Medscape, Merck Serono, Merck Sharp & Dohme, Novartis, PeerVoice, Pfizer, Prime Oncology, Roche, Roche Diagnostics/Ventana, Sanofi
- Jorge Bacigalupo, PSM, has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- Libby Lurwick has nothing to disclose.
- Tim Person has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Recognize the importance of testing for MET gene aberrations.
- Identify effective testing modalities for biomarker assessment.
- Summarize recent trial results and recognize how these affects current clinical practice.
- Identify new potential indications for MET inhibitors within NSCLC, such as a combination approach for EGFR TKI resistance.
- Understand guideline updates to treating patients with MET+ NSCLC.
- Implement treatment planning strategies that account for patient preferences and improve adherence.
This activity is designed to meet the educational needs of medical oncologists, pathologists, pulmonologists, and other healthcare providers who manage patients with NSCLC.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at firstname.lastname@example.org.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
AGILE – Academy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.
This activity is supported by an independent educational grant from the healthcare business of Merck KGaA, Darmstadt, Germany.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers1.00 program credit
Samuel J. Klempner, MD
Roy F. Chemaly, MD, MPH